Newron Pharmaceuticals S.p.A. announced the initiation of Study 008A, the first potentially pivotal study with evenamide in patients with schizophrenia. Study 008A, a four-week, randomized, double-blind placebo-controlled international study, is designed to evaluate the efficacy, tolerability, and safety (including effects on the electroencephalogram (EEG)) of the 30mg BID therapeutic dose of evenamide in patients with chronic schizophrenia, currently being treated with a second-generation antipsychotic. Newron plans to randomize at least 200 patients in study centers in Europe, Asia and Latin America. Results from the study are expected by Fourth Quarter 2022. This study is part of Newron's Phase III evenamide clinical trial program that targets patients with schizophrenia experiencing worsening of psychosis on therapeutic doses of atypical antipsychotics, as well as treatment-resistant patients. Newron is currently evaluating potential options for partnering/co-developing the further development of evenamide.